GlassScriptPhysician profile
Mathew Sawyer
NPI 1316054745
$3,071.72
in general payments reported to CMS, 2019-2025
21 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.14 · 2023: $354 · 2024: $1,065 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $945.55 | 2023-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $362.70 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $261.30 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $237.99 | 2023-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Novo Nordisk INC | $179.56 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Inspire Medical Systems, INC. | $148.95 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $141.33 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $124.88 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.48 | 2023-2024 | Jardiance |
| Collegium Pharmaceutical, INC. | $115.97 | 2024-2025 | Belbuca, Xtampza |
| Abiomed | $99.01 | 2024-2025 | Impella |
| Neurocrine Biosciences, INC. | $73.00 | 2024-2025 | Ingrezza |
| Sanofi-Aventis U.S. LLC | $46.53 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.95 | 2023 | Trintellix |
| Exact Sciences Corporation | $35.42 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.88 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.17 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $24.65 | 2025 | Voquezna |
| Aurinia Pharma U.S., INC. | $20.43 | 2022 | |
| Edwards Lifesciences Corporation | $15.35 | 2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $13.62 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Sawyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.